Your session is about to expire
← Back to Search
Axicabtagene Ciloleucel for Follicular Lymphoma (ZUMA-22 Trial)
ZUMA-22 Trial Summary
This trial is comparing a new treatment to the current standard of care for people with a certain type of lymphoma that has come back or doesn't respond to treatment. They will be looking at how well the new treatment works compared to the current standard by measuring how long people live without the disease getting worse.
ZUMA-22 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowZUMA-22 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 27 Patients • NCT04002401ZUMA-22 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer returned or didn't respond after initial treatment and it's considered high-risk.I have been diagnosed with small lymphocytic lymphoma.I need treatment for my condition.I have severe nerve pain or numbness.I am not pregnant or breastfeeding.I have not had serious heart problems in the last 6 months.I have been diagnosed with lymphoplasmacytic lymphoma.My condition is Follicular Lymphoma Grade 3b.I do not have an active infection with HIV, hepatitis B, or hepatitis C.I have previously received treatment targeting CD19.My lymphoma affects my heart.I have a significant brain or nerve condition.I have large B cell lymphoma or transformed follicular lymphoma.I do not have any untreated infections.I am not willing to use birth control.I have not had CAR T-cell therapy or any genetically modified T-cell treatment.My lymphoma has spread through the entire thickness of my stomach wall.I have a medical tube or drain in my body, but ports like Port-a-Cath are okay.I have a history of CNS lymphoma.My lymphoma is confirmed as follicular and is either grade 1, 2, or 3a.My kidney, liver, lung, and heart functions are all within normal ranges.
- Group 1: Standard of Care Therapy
- Group 2: Axicabtagene Ciloleucel
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In how many different states is this study being conducted?
"There are 4 running for this clinical trial including Dana-Farber Cancer Institute in Boston, Avera Cancer Institute in Sioux Falls, and TriStar Centennial Medical Center - Cell Processing in Nashville,along with other locations 4 other locations."
Has the FDA greenlit Axicabtagene Ciloleucel for patient use?
"There is some evidence of efficacy and multiple reports of safety, so our team gives Axicabtagene Ciloleucel a 3."
Are there any remaining places where people can sign up for this test?
"That is correct, the listing on clinicaltrials.gov verifies that this study is looking for additional patients. The trial was first advertised on September 22nd, 2022 and was last updated a little over two weeks ago on October 7th, 2022. The study needs to enroll 230 individuals at 4 different research centres."
Share this study with friends
Copy Link
Messenger